Volume Alert - AVNR 13.91 Avanir Pharmaceuticals Inc $AVNR Hit a high today of 14.20 Closing the day 10:30 at 13.91 +0.21 +1.53% With a day low of 13.66 and a total volume of 1,141,353.
AVNR Recent Posts: http://investorshangout.com/Avanir-Pharmaceut...VNR-53434/
AVNR Avanir Pharmaceuticals Inc Recent Headline News
Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:40PM CST
Avanir Pharmaceuticals, Inc. (AVNR) received a disappointing preliminary feedback from the FDA regarding its new drug application for AVP-825.
LCI: 46.89 (+0.19), AVNR: 13.86 (+0.16), AUXL: 33.20 (+0.51), GSK: 46.45 (+0.17)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.86 (+0.16), SGEN: 37.00 (-0.80), GILD: 102.37 (-1.34), ABBV: 65.67 (-0.38), GSK: 46.45 (+0.17)
Is New Hope Coming for Migraine Sufferers?
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 9:05AM CST
The Centers for Disease Control and Prevention estimates there are 37 million migraine sufferers in the U.S., and that roughly 13 million prescriptions are written annually for triptan medicines to treat those people. B ut there's a big problem: too...
AVNR: 13.86 (+0.16), GSK: 46.45 (+0.17)
Avanir Pharmaceuticals (AVNR) Stock Drops After FDA Provides New Drug Application Feedback
at The Street - Fri Nov 07, 10:25AM CST
Shares of Avanir Pharmaceuticals (AVNR) fell after the FDA provided preliminary written feedback to the biopharmaceutical company regarding its New Drug Application (NDA) for its migraine treatment drug AVP-825.
AVNR: 13.86 (+0.16)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST
BEBE: 2.58 (+0.01), ANET: 76.96 (+0.16), TKMR: 16.31 (-0.06), ORBC: 6.36 (+0.02), MDRX: 12.18 (-0.02), RMTI: 10.09 (-0.19), CTIC: 2.23 (-0.05), SHLD: 34.86 (-1.05), UBNT: 29.73 (+0.14), RIG: 25.50 (-0.35), KGC: 2.84 (-0.12), APT: 2.78 (+0.05), ANF: 29.11 (+0.17), MITK: 3.87 (-0.09), ZNGA: 2.71 (unch), CNET: 1.81 (-0.05), KING: 16.10 (unch), NETE: 1.34 (-0.01), SLXP: 105.06 (-0.33), RPRX: 9.12 (-0.07), NADL: 3.12 (-0.85), PGNX: 6.48 (-0.06), AVNR: 13.86 (+0.16), FSLR: 49.06 (-0.40), DVA: 75.16 (-0.07), NDLS: 22.43 (-0.22), ICPT: 156.31 (-6.19), AGIO: 98.30 (+14.49), PLNR: 7.24 (-0.15)
Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine
PR Newswire - Fri Nov 07, 7:30AM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued preliminary written feedback to its New Drug Application (NDA) for AVP-825. AVP-825 is a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally utilizing a novel Breath Powered delivery technology. The FDA has raised questions regarding the human factor validation study data submitted as part of the NDA. Human factor testing focuses on the interactions between people and devices. The goal of human factor testing is to evaluate use-related risks and confirm that users can use the device safely and effectively. Although the NDA review is ongoing, Avanir has concluded, at this time, that approval of AVP-825 may be unlikely by the PDUFA date of November, 26, 2014.
AVNR: 13.86 (+0.16)
Avanir moves up on takeout speculation
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:11AM CST
AVNR: 13.86 (+0.16)
Will Avanir Pharmaceuticals (AVNR) Stock React Today to This Analyst Action?
at The Street - Tue Nov 04, 7:52AM CST
Deutsche Bank initiated coverage of Avanir Pharmaceuticals (AVNR) with a 'buy' rating and a price target of $17.
AVNR: 13.86 (+0.16)
Looking For My Next Triple In Biotech
Bret Jensen - at Seeking Alpha - Fri Oct 31, 12:26PM CDT
PGNX: 6.48 (-0.06), AVNR: 13.86 (+0.16), XOMA: 4.24 (+0.18)
Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache"
PR Newswire - Thu Oct 30, 3:01PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of results from TARGET, a pivotal phase III study evaluating the efïcacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available). AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder (22mg) delivered intranasally utilizing a novel Breath Powered(TM) delivery technology, for the acute treatment of migraine. A New Drug Application (NDA) for AVP-825 has been accepted and is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of November 26, 2014.
AVNR: 13.86 (+0.16)
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt
PR Newswire - Mon Oct 20, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Mallinckrodt PLC (NYSE: MNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 17, 2014, the NASDAQ Composite ended at 4,258.44, up 0.97%, the Dow Jones Industrial Average advanced 1.63%, to finish the day at 16,380.41, and the S&P 500 closed at 1,886.76, up 1.29%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index also advancing 0.29% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MNK: 84.98 (-3.82), ZTS: 43.44 (-0.75), AGN: 213.21 (-0.16), AVNR: 13.86 (+0.16), ACT: 268.00 (-1.60)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 303.62 (-1.94), MNOV: 2.99 (+0.11), CHTP: 6.52 (-0.03), ADMS: 14.54 (-0.05), ACOR: 34.89 (+0.36), BCLI: 3.26 (-0.11), BSX: 13.29 (-0.39), IPXL: 30.03 (+0.49), AVNR: 13.86 (+0.16), ACAD: 27.67 (-0.12), CVTS: (), MRK: 59.70 (-0.19), TEVA: 57.35 (+0.12), PRTA: 22.95 (-0.15), PRAN: 1.64 (-0.01), FOLD: 6.54 (-0.21), CUR: 2.83 (-0.02)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 13.86 (+0.16), OHRP: 7.44 (+0.08), MNKD: 6.49 (-0.11), ARNA: 4.09 (-0.22)
Intra-Cellular Therapies Reveals Top-line Data on ITI-007 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:50PM CDT
Intra-Cellular Therapies, Inc. (ITCI) announced top-line results from a phase I/II study (ITI-007-200) on the company's lead candidate, ITI-007.
MDVN: 109.71 (+1.59), AVNR: 13.86 (+0.16), LGND: 54.47 (-0.12), ITCI: 14.54 (+0.17)
Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:04PM CDT
Concert Pharmaceuticals, Inc. (CNCE) recently announced encouraging data from a phase I study on CTP-354.
AVNR: 13.86 (+0.16), SHPG: 209.03 (-0.97), JAZZ: 171.89 (-0.43), CNCE: 12.83 (-0.24)
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 13.86 (+0.16), UTHR: 128.78 (+0.57), PCRX: 91.08 (+0.34), HPTX: 20.98 (unch)
Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting
PR Newswire - Mon Oct 13, 3:26PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association Meeting.
AVNR: 13.86 (+0.16)
Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014
PR Newswire - Wed Oct 08, 3:15PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New York City. At the meeting, members of the Avanir senior management team will provide a company update and discuss the results from the phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.
AVNR: 13.86 (+0.16)
Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease
PR Newswire - Wed Oct 08, 7:30AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from the phase II trial evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease (AD) and the results of the phase IV PRISM II study evaluating NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) for the treatment of pseudobulbar affect (PBA) in patients with AD will be presented at the American Neurological Association's (ANA) Annual Meeting being held at the Marriott Waterfront Hotel in Baltimore, Maryland, October 12-14, 2014.
AVNR: 13.86 (+0.16)
Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon Sep 29, 8:15AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the closing of its previously announced public offering of 20,930,000 shares of its common stock, including 2,730,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $11.00 per share, before underwriting discounts. J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch acted as joint book-running managers for the offering. Piper Jaffray and JMP Securities acted as co-managers for the offering.
AVNR: 13.86 (+0.16), JPM: 60.73 (+0.20), DB: 30.85 (+0.25)
AVNR Recent Posts: http://investorshangout.com/Avanir-Pharmaceut...VNR-53434/
AVNR Avanir Pharmaceuticals Inc Recent Headline News
Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:40PM CST
Avanir Pharmaceuticals, Inc. (AVNR) received a disappointing preliminary feedback from the FDA regarding its new drug application for AVP-825.
LCI: 46.89 (+0.19), AVNR: 13.86 (+0.16), AUXL: 33.20 (+0.51), GSK: 46.45 (+0.17)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.86 (+0.16), SGEN: 37.00 (-0.80), GILD: 102.37 (-1.34), ABBV: 65.67 (-0.38), GSK: 46.45 (+0.17)
Is New Hope Coming for Migraine Sufferers?
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 9:05AM CST
The Centers for Disease Control and Prevention estimates there are 37 million migraine sufferers in the U.S., and that roughly 13 million prescriptions are written annually for triptan medicines to treat those people. B ut there's a big problem: too...
AVNR: 13.86 (+0.16), GSK: 46.45 (+0.17)
Avanir Pharmaceuticals (AVNR) Stock Drops After FDA Provides New Drug Application Feedback
at The Street - Fri Nov 07, 10:25AM CST
Shares of Avanir Pharmaceuticals (AVNR) fell after the FDA provided preliminary written feedback to the biopharmaceutical company regarding its New Drug Application (NDA) for its migraine treatment drug AVP-825.
AVNR: 13.86 (+0.16)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST
BEBE: 2.58 (+0.01), ANET: 76.96 (+0.16), TKMR: 16.31 (-0.06), ORBC: 6.36 (+0.02), MDRX: 12.18 (-0.02), RMTI: 10.09 (-0.19), CTIC: 2.23 (-0.05), SHLD: 34.86 (-1.05), UBNT: 29.73 (+0.14), RIG: 25.50 (-0.35), KGC: 2.84 (-0.12), APT: 2.78 (+0.05), ANF: 29.11 (+0.17), MITK: 3.87 (-0.09), ZNGA: 2.71 (unch), CNET: 1.81 (-0.05), KING: 16.10 (unch), NETE: 1.34 (-0.01), SLXP: 105.06 (-0.33), RPRX: 9.12 (-0.07), NADL: 3.12 (-0.85), PGNX: 6.48 (-0.06), AVNR: 13.86 (+0.16), FSLR: 49.06 (-0.40), DVA: 75.16 (-0.07), NDLS: 22.43 (-0.22), ICPT: 156.31 (-6.19), AGIO: 98.30 (+14.49), PLNR: 7.24 (-0.15)
Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine
PR Newswire - Fri Nov 07, 7:30AM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued preliminary written feedback to its New Drug Application (NDA) for AVP-825. AVP-825 is a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally utilizing a novel Breath Powered delivery technology. The FDA has raised questions regarding the human factor validation study data submitted as part of the NDA. Human factor testing focuses on the interactions between people and devices. The goal of human factor testing is to evaluate use-related risks and confirm that users can use the device safely and effectively. Although the NDA review is ongoing, Avanir has concluded, at this time, that approval of AVP-825 may be unlikely by the PDUFA date of November, 26, 2014.
AVNR: 13.86 (+0.16)
Avanir moves up on takeout speculation
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:11AM CST
AVNR: 13.86 (+0.16)
Will Avanir Pharmaceuticals (AVNR) Stock React Today to This Analyst Action?
at The Street - Tue Nov 04, 7:52AM CST
Deutsche Bank initiated coverage of Avanir Pharmaceuticals (AVNR) with a 'buy' rating and a price target of $17.
AVNR: 13.86 (+0.16)
Looking For My Next Triple In Biotech
Bret Jensen - at Seeking Alpha - Fri Oct 31, 12:26PM CDT
PGNX: 6.48 (-0.06), AVNR: 13.86 (+0.16), XOMA: 4.24 (+0.18)
Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache"
PR Newswire - Thu Oct 30, 3:01PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of results from TARGET, a pivotal phase III study evaluating the efïcacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available). AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder (22mg) delivered intranasally utilizing a novel Breath Powered(TM) delivery technology, for the acute treatment of migraine. A New Drug Application (NDA) for AVP-825 has been accepted and is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of November 26, 2014.
AVNR: 13.86 (+0.16)
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt
PR Newswire - Mon Oct 20, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Mallinckrodt PLC (NYSE: MNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 17, 2014, the NASDAQ Composite ended at 4,258.44, up 0.97%, the Dow Jones Industrial Average advanced 1.63%, to finish the day at 16,380.41, and the S&P 500 closed at 1,886.76, up 1.29%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index also advancing 0.29% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MNK: 84.98 (-3.82), ZTS: 43.44 (-0.75), AGN: 213.21 (-0.16), AVNR: 13.86 (+0.16), ACT: 268.00 (-1.60)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 303.62 (-1.94), MNOV: 2.99 (+0.11), CHTP: 6.52 (-0.03), ADMS: 14.54 (-0.05), ACOR: 34.89 (+0.36), BCLI: 3.26 (-0.11), BSX: 13.29 (-0.39), IPXL: 30.03 (+0.49), AVNR: 13.86 (+0.16), ACAD: 27.67 (-0.12), CVTS: (), MRK: 59.70 (-0.19), TEVA: 57.35 (+0.12), PRTA: 22.95 (-0.15), PRAN: 1.64 (-0.01), FOLD: 6.54 (-0.21), CUR: 2.83 (-0.02)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 13.86 (+0.16), OHRP: 7.44 (+0.08), MNKD: 6.49 (-0.11), ARNA: 4.09 (-0.22)
Intra-Cellular Therapies Reveals Top-line Data on ITI-007 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:50PM CDT
Intra-Cellular Therapies, Inc. (ITCI) announced top-line results from a phase I/II study (ITI-007-200) on the company's lead candidate, ITI-007.
MDVN: 109.71 (+1.59), AVNR: 13.86 (+0.16), LGND: 54.47 (-0.12), ITCI: 14.54 (+0.17)
Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:04PM CDT
Concert Pharmaceuticals, Inc. (CNCE) recently announced encouraging data from a phase I study on CTP-354.
AVNR: 13.86 (+0.16), SHPG: 209.03 (-0.97), JAZZ: 171.89 (-0.43), CNCE: 12.83 (-0.24)
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 13.86 (+0.16), UTHR: 128.78 (+0.57), PCRX: 91.08 (+0.34), HPTX: 20.98 (unch)
Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting
PR Newswire - Mon Oct 13, 3:26PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association Meeting.
AVNR: 13.86 (+0.16)
Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014
PR Newswire - Wed Oct 08, 3:15PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New York City. At the meeting, members of the Avanir senior management team will provide a company update and discuss the results from the phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.
AVNR: 13.86 (+0.16)
Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease
PR Newswire - Wed Oct 08, 7:30AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from the phase II trial evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease (AD) and the results of the phase IV PRISM II study evaluating NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) for the treatment of pseudobulbar affect (PBA) in patients with AD will be presented at the American Neurological Association's (ANA) Annual Meeting being held at the Marriott Waterfront Hotel in Baltimore, Maryland, October 12-14, 2014.
AVNR: 13.86 (+0.16)
Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon Sep 29, 8:15AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the closing of its previously announced public offering of 20,930,000 shares of its common stock, including 2,730,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $11.00 per share, before underwriting discounts. J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch acted as joint book-running managers for the offering. Piper Jaffray and JMP Securities acted as co-managers for the offering.
AVNR: 13.86 (+0.16), JPM: 60.73 (+0.20), DB: 30.85 (+0.25)
